Alveus

Cardiometabolic Therapeutics · Prescription Drugs
$56.9Mlatest round · Venture round · Dec 2025 · 10 mo ago
2backers · Jeito Capital, Omega Funds
49+team · French register · Dec 2023
17stories in the press

Overview

At Alveus Therapeutics, we are building a differentiated therapeutic portfolio that delivers sustainable weight loss with superior tolerability.

Funding and backers

Total raised
$56.9M
1 round on record
Latest round
$56.9M
Venture round · Dec 2025 · 10 mo ago
Team
50–99
French register · Dec 2023
Backers
2
Jeito Capital, Omega Funds
The money's age
Fresh money
10 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 20 Launched Equipped with $160M series A, Alveus debuts into crowded obesity development landscape · alveustx.com Dec 22, 2025 Raised a round Venture round $56.9M · SEC Form D Aug 1, 2014 Founded per the company register
Tractionpublic signals, read monthly
Web presence
top 8%
of 133.2M domains by links, Common Crawl
Funding rounds
RoundDateAmountInvestorsSource
Venture round Dec 2025 $56.9M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Alveus Therapeutics, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Raj KannanExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Jeito Capital fund Omega Funds fund
Investors in similar startupsfunds that back the companies most like this one
High-Tech Gründerfonds
backs Sedivention, REVIER Therapeutics
Plug and Play
backs CardiaTec Biosciences
Cambridge Angels
backs CardiaTec Biosciences
RA Capital Management
backs Sparrow Pharmaceuticals
Cambridge Enterprise
backs CardiaTec Biosciences
OrbiMed
backs Sparrow Pharmaceuticals
Similar startupsby what they do, their industry and backers
REVIER TherapeuticsFounded 2020
Revier Therapeutics has established the first therapeutic approach to selectively target class IIa HDACs to treat cardiometabolic diseases…
SediventionFounded 2021
Fight obesity within 20 minutes - fast, effective, long-term. A new weight-loss therapy for the treatment of obesity. Just a view minutes…
StarnatxSeries B $40M · 6 mo ago · Founded 2021 · 51-200 employees
星锐医药(Starna Therapeutics) 成立于2021年8月，公司聚焦肝外靶向递送技术，致力于研发以RNA为核心的创新药物，解决未被满足的临床需求。核心团队来自知名药企、高校和研究院所，团队拥有深厚的核酸药物发现、递送技术和制剂开发能力。.
CardiaTec BiosciencesVenture round · 2 yr ago
CardiaTec is a TechBio company leveraging large scale multiomics data to discover novel cardiovascular therapeutics.
HeartPoint GlobalVenture round $3.3M · 7 yr ago · Founded 2018 · 11-50 employees
HeartPoint Global is developing investigational catheter-based technologies designed to provide minimally invasive alternatives for…
Sparrow Pharmaceuticals51-200 employees
Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of…

Financials

Total raised
$56.9M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
Round Announced Amount
Venture - Series Unknown 2025 $56.9M Details

People

Raj Kannan
Executive Officer, Director
SEC Form D
Gregory Parekh
Director
SEC Form D
Ivan Gergel
Director
SEC Form D
Garrett Ingram
Director
SEC Form D
Carlo de Notaristefani
Director
SEC Form D
Ameet Nathwani
Director
SEC Form D
Jan Van de Bossche
Director
SEC Form D
Claudio Nessi
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Connections

List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors2
Jeito CapitalVia a fund
22 portfolio companies: Odyssey, Adcendo, Bionyra Pharma and 19 more
Omega FundsVia a fund
160 portfolio companies: Windward Bio, Xiimedical, Xtuit and 157 more
Report a mistake

News

Blog 2 months ago
Alveus Therapeutics Initiates Phase 2 PRESERVE Trial to Evaluate ALV-100 for Chronic Weight Management Read more
Report
Blog 2 months ago
Alveus Therapeutics taps Novo Nordisk veteran for executive role Read more
Report
Blog 2 months ago
Alveus Therapeutics Strengthens Executive Leadership Team, Opens Boston office Read more
Report
Blog 8 months ago
Alveus: Best-in-class opportunity in obesity Read more
Report
News Pulse 2.0 8 months ago
Alveus Therapeutics: $197 Million Series A Raised To Advance Next-Generation Obesity And Metabolic Disease Therapies
Alveus Therapeutics announced the second and final closing of its oversubscribed Series A financing, increasing the total round size to $197 million. The clinical-stage biotechnology company, which is developing next-generation therapies for obesity and m
Read more
Report
Blog 9 months ago
Obesity company closes capital raising of DKK 1.2 billion - brings Novo Holdings on board Read more
Report
Press release 9 months ago
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next-Generation Therapies for Obesity and Metabolic Diseases Read more
Report
Press release 9 months ago
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next-Generation Therapies for Obesity and Metabolic Diseases Read more
Report
Blog 9 months ago
Han forlod Novo for at bygge nyt fedmeselskab op fra bunden: "I sidste ende føles det helt rigtigt" Read more
Report
Press release 9 months ago
Equipped with $160M series A, Alveus debuts into crowded obesity development landscape Read more
Report
Show more news

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Paris France
HQ
10-50 est. staff